$1.68 EPS Expected for Quest Diagnostics Incorporated (DGX)

September 16, 2018 - By Carolyn Hewitt

Quest Diagnostics Incorporated (NYSE:DGX) LogoInvestors sentiment increased to 0.93 in Q2 2018. Its up 0.13, from 0.8 in 2018Q1. It improved, as 30 investors sold Quest Diagnostics Incorporated shares while 204 reduced holdings. 72 funds opened positions while 145 raised stakes. 110.90 million shares or 0.82% less from 111.81 million shares in 2018Q1 were reported.
Kentucky Retirement Ins Trust Fund invested in 2,558 shares. Motco reported 0% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Pggm Invs has invested 0.32% in Quest Diagnostics Incorporated (NYSE:DGX). Argent Trust holds 0.37% or 24,922 shares. Principal Financial Grp Inc Inc holds 0.03% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX) for 338,737 shares. Willingdon Wealth accumulated 58 shares. Whittier Tru Company stated it has 0% in Quest Diagnostics Incorporated (NYSE:DGX). Parsons Cap Management Incorporated Ri invested in 0.16% or 12,852 shares. Davis Selected Advisers holds 0.06% or 133,157 shares. First Quadrant Lp Ca holds 8,400 shares. Pictet Asset Limited invested in 0.02% or 79,508 shares. Baker Ellis Asset Ltd Company holds 0.05% or 1,700 shares in its portfolio. Park Avenue Secs Limited Liability Company accumulated 3,015 shares or 0.06% of the stock. 2,142 were reported by Ronna Sue Cohen. 2,337 were reported by Loomis Sayles And L P.

Since May 25, 2018, it had 0 insider purchases, and 6 selling transactions for $40.17 million activity. 168,490 shares were sold by RUSCKOWSKI STEPHEN H, worth $18.03M. Cunningham Everett also sold $7.47M worth of Quest Diagnostics Incorporated (NYSE:DGX) on Monday, July 2. The insider GUINAN MARK sold 61,533 shares worth $6.50M. Another trade for 30,780 shares valued at $3.48 million was made by PREVOZNIK MICHAEL E on Tuesday, July 10.

Analysts expect Quest Diagnostics Incorporated (NYSE:DGX) to report $1.68 EPS on October, 18.They anticipate $0.29 EPS change or 20.86 % from last quarter’s $1.39 EPS. DGX’s profit would be $229.60 million giving it 16.10 P/E if the $1.68 EPS is correct. After having $1.75 EPS previously, Quest Diagnostics Incorporated’s analysts see -4.00 % EPS growth. The stock increased 0.02% or $0.02 during the last trading session, reaching $108.19. About 851,112 shares traded or 0.06% up from the average. Quest Diagnostics Incorporated (NYSE:DGX) has risen 0.34% since September 16, 2017 and is uptrending. It has underperformed by 15.28% the S&P500.

Quest Diagnostics Incorporated (NYSE:DGX) Ratings Coverage

Among 11 analysts covering Quest Diagnostics (NYSE:DGX), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Quest Diagnostics had 11 analyst reports since March 19, 2018 according to SRatingsIntel. The rating was reinitiated by Robert W. Baird on Tuesday, May 1 with “Outperform”. As per Monday, March 19, the company rating was maintained by Canaccord Genuity. The company was maintained on Friday, September 14 by Argus Research. Barclays Capital upgraded the shares of DGX in report on Monday, June 25 to “Buy” rating. The rating was upgraded by William Blair to “Buy” on Friday, June 8. The company was maintained on Friday, May 25 by Mizuho. On Wednesday, June 27 the stock rating was downgraded by Deutsche Bank to “Hold”. The rating was upgraded by Morgan Stanley on Tuesday, May 29 to “Overweight”. The firm has “Outperform” rating by Credit Suisse given on Friday, May 25. The firm has “Outperform” rating given on Tuesday, July 10 by Evercore.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $14.79 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 18.62 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.